Literature DB >> 24871971

Genotype-phenotype correlations for infants and children with ABCA3 deficiency.

Jennifer A Wambach1, Alicia M Casey, Martha P Fishman, Daniel J Wegner, Susan E Wert, F Sessions Cole, Aaron Hamvas, Lawrence M Nogee.   

Abstract

RATIONALE: Recessive mutations in the ATP-binding cassette transporter A3 (ABCA3) cause lethal neonatal respiratory failure and childhood interstitial lung disease. Most ABCA3 mutations are private.
OBJECTIVES: To determine genotype-phenotype correlations for recessive ABCA3 mutations.
METHODS: We reviewed all published and unpublished ABCA3 sequence and phenotype data from our prospective genetic studies of symptomatic infants and children at Washington and Johns Hopkins Universities. Mutations were classified based on their predicted disruption of protein function: frameshift and nonsense mutations were classified as "null," whereas missense, predicted splice site mutations, and insertion/deletions were classified as "other." We compared age of presentation and outcomes for the three genotypes: null/null, null/other, and other/other.
MEASUREMENTS AND MAIN RESULTS: We identified 185 infants and children with homozygous or compound heterozygous ABCA3 mutations and lung disease. All of the null/null infants presented with respiratory failure at birth compared with 75% of infants with null/other or other/other genotypes (P = 0.00011). By 1 year of age, all of the null/null infants had died or undergone lung transplantation compared with 62% of the null/other and other/other children (P < 0.0001).
CONCLUSIONS: Genotype-phenotype correlations exist for homozygous or compound heterozygous mutations in ABCA3. Frameshift or nonsense ABCA3 mutations are predictive of neonatal presentation and poor outcome, whereas missense, splice site, and insertion/deletions are less reliably associated with age of presentation and prognosis. Counseling and clinical decision making should acknowledge these correlations.

Entities:  

Keywords:  childhood interstitial lung disease; neonatal respiratory distress; surfactant

Mesh:

Substances:

Year:  2014        PMID: 24871971      PMCID: PMC4226019          DOI: 10.1164/rccm.201402-0342OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  33 in total

1.  ABCA3 is a lamellar body membrane protein in human lung alveolar type II cells.

Authors:  G Yamano; H Funahashi; O Kawanami; L X Zhao; N Ban; Y Uchida; T Morohoshi; J Ogawa; S Shioda; N Inagaki
Journal:  FEBS Lett       Date:  2001-11-16       Impact factor: 4.124

2.  ABCA3-mediated choline-phospholipids uptake into intracellular vesicles in A549 cells.

Authors:  Yoshihiro Matsumura; Hiromichi Sakai; Mayumi Sasaki; Nobuhiro Ban; Nobuya Inagaki
Journal:  FEBS Lett       Date:  2007-06-06       Impact factor: 4.124

3.  ABCA3 mutations associated with pediatric interstitial lung disease.

Authors:  Janine E Bullard; Susan E Wert; Jeffrey A Whitsett; Michael Dean; Lawrence M Nogee
Journal:  Am J Respir Crit Care Med       Date:  2005-06-23       Impact factor: 21.405

4.  ABCA3 as a lipid transporter in pulmonary surfactant biogenesis.

Authors:  Nobuhiro Ban; Yoshihiro Matsumura; Hiromichi Sakai; Yasukazu Takanezawa; Mayumi Sasaki; Hiroyuki Arai; Nobuya Inagaki
Journal:  J Biol Chem       Date:  2007-01-30       Impact factor: 5.157

5.  Identification of LBM180, a lamellar body limiting membrane protein of alveolar type II cells, as the ABC transporter protein ABCA3.

Authors:  Surafel Mulugeta; Joseph M Gray; Kathleen L Notarfrancesco; Linda W Gonzales; Michael Koval; Sheldon I Feinstein; Philip L Ballard; Aron B Fisher; Henry Shuman
Journal:  J Biol Chem       Date:  2002-04-08       Impact factor: 5.157

6.  Usual interstitial pneumonia in an adolescent with ABCA3 mutations.

Authors:  Lisa R Young; Lawrence M Nogee; Bruce Barnett; Ralph J Panos; Thomas V Colby; Gail H Deutsch
Journal:  Chest       Date:  2008-07       Impact factor: 9.410

7.  Heterozygosity for ABCA3 mutations modifies the severity of lung disease associated with a surfactant protein C gene (SFTPC) mutation.

Authors:  Janine E Bullard; Lawrence M Nogee
Journal:  Pediatr Res       Date:  2007-08       Impact factor: 3.756

Review 8.  Genetic disorders of surfactant dysfunction.

Authors:  Susan E Wert; Jeffrey A Whitsett; Lawrence M Nogee
Journal:  Pediatr Dev Pathol       Date:  2009 Jul-Aug

9.  Genotype-phenotype correlations for infants and children with ABCA3 deficiency.

Authors:  Jennifer A Wambach; Alicia M Casey; Martha P Fishman; Daniel J Wegner; Susan E Wert; F Sessions Cole; Aaron Hamvas; Lawrence M Nogee
Journal:  Am J Respir Crit Care Med       Date:  2014-06-15       Impact factor: 21.405

10.  An intronic ABCA3 mutation that is responsible for respiratory disease.

Authors:  Amit Agrawal; Aaron Hamvas; F Sessions Cole; Jennifer A Wambach; Daniel Wegner; Carl Coghill; Keith Harrison; Lawrence M Nogee
Journal:  Pediatr Res       Date:  2012-02-15       Impact factor: 3.756

View more
  58 in total

Review 1.  Cystinuria: genetic aspects, mouse models, and a new approach to therapy.

Authors:  Amrik Sahota; Jay A Tischfield; David S Goldfarb; Michael D Ward; Longqin Hu
Journal:  Urolithiasis       Date:  2018-12-04       Impact factor: 3.436

2.  EMC3 coordinates surfactant protein and lipid homeostasis required for respiration.

Authors:  Xiaofang Tang; John M Snowball; Yan Xu; Cheng-Lun Na; Timothy E Weaver; Geremy Clair; Jennifer E Kyle; Erika M Zink; Charles Ansong; Wei Wei; Meina Huang; Xinhua Lin; Jeffrey A Whitsett
Journal:  J Clin Invest       Date:  2017-10-30       Impact factor: 14.808

Review 3.  Surfactant protein disorders in childhood interstitial lung disease.

Authors:  Jagdev Singh; Adam Jaffe; André Schultz; Hiran Selvadurai
Journal:  Eur J Pediatr       Date:  2021-04-11       Impact factor: 3.183

4.  Increased Risk of Interstitial Lung Disease in Children with a Single R288K Variant of ABCA3.

Authors:  Thomas Wittmann; Sabrina Frixel; Stefanie Höppner; Ulrike Schindlbeck; Andrea Schams; Matthias Kappler; Jan Hegermann; Christoph Wrede; Gerhard Liebisch; Anne Vierzig; Angela Zacharasiewicz; Matthias Volkmar Kopp; Christian F Poets; Winfried Baden; Dominik Hartl; Anton H van Kaam; Peter Lohse; Charalampos Aslanidis; Ralf Zarbock; Matthias Griese
Journal:  Mol Med       Date:  2016-02-26       Impact factor: 6.354

5.  Outcomes of Lung Transplantation for Infants and Children with Genetic Disorders of Surfactant Metabolism.

Authors:  Whitney B Eldridge; Qunyuan Zhang; Albert Faro; Stuart C Sweet; Pirooz Eghtesady; Aaron Hamvas; F Sessions Cole; Jennifer A Wambach
Journal:  J Pediatr       Date:  2017-02-16       Impact factor: 4.406

Review 6.  Contributions of alveolar epithelial cell quality control to pulmonary fibrosis.

Authors:  Jeremy Katzen; Michael F Beers
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

Review 7.  Familial Interstitial Lung Disease.

Authors:  Jonathan A Kropski
Journal:  Semin Respir Crit Care Med       Date:  2020-04-12       Impact factor: 3.119

Review 8.  Interstitial lung disease in newborns.

Authors:  Lawrence M Nogee
Journal:  Semin Fetal Neonatal Med       Date:  2017-03-28       Impact factor: 3.926

9.  Pulmonary Aptamer Signatures in Children's Interstitial and Diffuse Lung Disease.

Authors:  Robin R Deterding; Brandie D Wagner; J Kirk Harris; Emily M DeBoer
Journal:  Am J Respir Crit Care Med       Date:  2019-12-15       Impact factor: 21.405

Review 10.  Approaching Clinical Trials in Childhood Interstitial Lung Disease and Pediatric Pulmonary Fibrosis.

Authors:  Robin R Deterding; Emily M DeBoer; Michal J Cidon; Terry E Robinson; David Warburton; Gail H Deutsch; Lisa R Young
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.